drugset / Trial / NCT02416622

Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

NCT02416622 ↗

Phase 1/2 Completed 27 enrolled Beacon Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.

Timeline

Start
2015-05
Primary completion
2019-04
Completion
2023-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject rAAV2tYF-CB-hRS1 Gene therapy (AAV / viral vector) — Intravitreal